Skip to main content

Table 1 Basic characteristics of CVOTs started after 2008 FDA regulation

From: Updates on cardiovascular outcome trials in diabetes

  Study status Drug Drug class Intervention Primary outcome N Follow-up (years) Start and estimated end date Clinicaltrials.gov ID
SAVOR-TIMI53 Completed Saxagliptin DPP-4 inhibitor Addition of saxagliptin vs. placebo to usual diabetes care CV death, MI, or stroke 18,206 2.1 05.2010–05.2013 NCT01107886
EXAMINE Completed Alogliptin DPP-4 inhibitor Addition of alogliptin vs. placebo to usual diabetes care CV death, MI, or stroke 5380 1.5 10.2009–06.2013 NCT00968708
TECOS Completed Sitagliptin DPP-4 inhibitor Sitagliptin vs. placebo CV death, MI, UA, or stroke 14,724 3 12.2008–03.2015 NCT00790205
ELIXA Completed Lixisenatide GLP-1 receptor agonist Lixisenatide vs. placebo CV death, MI, UA, or stroke 6076 2.1 06.2010–02.2015 NCT01147250
EMPA-REG OUTCOME Completed Empagliflozin SGLT-2 inhibitor Empagliflozin 10 mg vs. empagliflozin 25 mg vs. placebo CV death, MI, or stroke 7000 3.1 07.2010–04.2015 NCT01131676
LEADER Completed Liraglutide GLP-1 receptor agonist Liraglutide vs. placebo CV death, MI, or stroke 9340 3.8 08.2010–12.2015 NCT01179048
SUSTAIN-6 Completed Semaglutide GLP-1 receptor agonist Semaglutide 0.5 mg vs. semaglutide 1.0 mg vs. placebo CV death, MI, or stroke 3299 1.9 02.2013–01.2016 NCT01720446
EXSCEL Completed Exenatide GLP-1 receptor agonist Exenatide once-weekly vs. placebo CV death, MI, or stroke 14,752 3.2 06.2010–04.2017 NCT01144338
CAROLINA Ongoing, not recruiting Linagliptin DPP-4 inhibitor Linagliptin vs. sulfonylureas vs. placebo CV death, MI, UA, or stroke 6000 10.2010–03.2019 NCT01243424
REWIND Ongoing, not recruiting Dulaglutide GLP-1 receptor agonist Dulaglutide vs. placebo CV death, MI, or stroke 9622 07.2011–07.2018 NCT01394952
ITCA650 Completed Exenatide in DUROS GLP-1 receptor agonist ITCA 650 (exenatide in DUROS) vs. placebo CV death, MI, UA, or stroke 4000 03.2013–03.2016 NCT01455896
DECLARE-TIMI Ongoing, not recruiting Dapagliflozin SGLT-2 inhibitor Dapagliflozin 10 mg vs. placebo CV death, MI, or stroke 17,276 01.2013–04.2019 NCT01730534
CARMELINA Ongoing, not recruiting Linagliptin DPP-4 inhibitor Linagliptin vs. placebo CV death, MI, UA, or stroke 8000 07.2013–12.2017 NCT01897532
DEVOTE Completed Insulin degludec Basal insulins Insulin degludec vs. insulin glargine CV death, MI, or stroke 7637 1.9 10.2013–10.2016 NCT01959529
MK-3102 Terminated MK-3102 DPP-4 inhibitor MK-3102 vs. placebo CV death, MI, UA, or stroke 4202 10.2012–03.2017 NCT01703208
VERTIS Ongoing, not recruiting Ertugliflozin SGLT-2 inhibitor Ertugliflozin 5 mg vs. ertugliflozin 15 mg vs. placebo CV death, MI, or stroke 3900 11.2013–10.2019 NCT01986881
CANVAS program Completed Canagliflozin SGLT-2 inhibitor Canagliflozin 100 mg vs. canagliflozin 300 mg vs. placebo CV death, MI or stroke 10,142 1.5 12.2009–02.2017 NCT01032629
Albiglutide trial Ongoing, not recruiting Albiglutide GLP-1 receptor agonist Albiglutide 30 mg vs. albiglutide 50 mg vs. placebo CV death, MI or stroke 9400 07.2015–02.2018 NCT02465515
ACE Completed Acarbose α-Glucosidase inhibitor Acarbose vs. placebo CV death, MI or stroke 6522 5.0 02.2009–04.2017 NCT00829660